Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 2(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03759275Completed

pMDT in Thoracic Surgery--------For the Baseline Investigation and Technical Preparation Stage

Role: collaborator

NCT03761550Completed

pMDT in Thoracic Surgery--The Process Implementation Stage

Role: collaborator

NCT03351062Phase 3Unknown

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Role: collaborator

NCT01757366Phase 2Unknown

Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

Role: lead

NCT01836120Phase 2Unknown

A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

Role: lead

NCT01492543Phase 2Unknown

Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

Role: collaborator

NCT01737216Phase 2Unknown

Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer

Role: lead

NCT01718626Phase 2Unknown

Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer

Role: lead

All 8 trials loaded